share_log

雲白國際:中期報告 2024

YNBY INTL: Interim Report 2024

HKEX ·  Sep 12, 2024 23:07

Summary by Moomoo AI

云白国际(YNBY INTL)於2024年6月30日公布未經審核的中期財務報告,顯示其貨品及商品貿易業務收益輕微上升1.6%,達到約362,300,000港元,但毛利率下降及一般及行政開支增加導致溢利減少。報告期內,每股基本及攤薄盈利為0.02港仙。截至2024年6月30日,公司現金及現金等價物約為179,300,000港元,資產總值約為345,300,000港元。董事會未建議派發中期股息。公司股東權益輕微增加至約244,300,000港元。公司面臨的挑戰包括全球經濟形勢、中國貿易業務的下行壓力及中國化妝品及健康品市場的穩定增長。公司將繼續推動貨品及商品貿易業務的增長。公司董事會成員多元化,並已設立提名委員會、薪酬委員會及審核委員會以監督公司治理。公司於報告期內遵守企業管治常規守則,惟董事會主席未能出席年會。公司購股權計劃已於2023年屆滿,期內無購股權獲授出或行使。
云白国际(YNBY INTL)於2024年6月30日公布未經審核的中期財務報告,顯示其貨品及商品貿易業務收益輕微上升1.6%,達到約362,300,000港元,但毛利率下降及一般及行政開支增加導致溢利減少。報告期內,每股基本及攤薄盈利為0.02港仙。截至2024年6月30日,公司現金及現金等價物約為179,300,000港元,資產總值約為345,300,000港元。董事會未建議派發中期股息。公司股東權益輕微增加至約244,300,000港元。公司面臨的挑戰包括全球經濟形勢、中國貿易業務的下行壓力及中國化妝品及健康品市場的穩定增長。公司將繼續推動貨品及商品貿易業務的增長。公司董事會成員多元化,並已設立提名委員會、薪酬委員會及審核委員會以監督公司治理。公司於報告期內遵守企業管治常規守則,惟董事會主席未能出席年會。公司購股權計劃已於2023年屆滿,期內無購股權獲授出或行使。
YNBY INTL announced its unaudited interim financial report on June 30, 2024, showing a slight increase of 1.6% in the revenue of its commodity trading business, reaching approximately 362.3 million Hong Kong dollars. However, the gross margin decreased and general and administrative expenses increased, leading to a reduction in profits. During the reporting period, the basic and diluted earnings per share were 0.02 Hong Kong cents. As of June 30, 2024, the company's cash and cash equivalents were approximately 179.3 million Hong Kong dollars, with total assets of about 345.3 million Hong Kong dollars. The board of directors did not recommend the payment of interim dividends. The company's shareholder equity increased slightly to approximately 244.3 million Hong Kong dollars. The company faces challenges including the global economic situation...Show More
YNBY INTL announced its unaudited interim financial report on June 30, 2024, showing a slight increase of 1.6% in the revenue of its commodity trading business, reaching approximately 362.3 million Hong Kong dollars. However, the gross margin decreased and general and administrative expenses increased, leading to a reduction in profits. During the reporting period, the basic and diluted earnings per share were 0.02 Hong Kong cents. As of June 30, 2024, the company's cash and cash equivalents were approximately 179.3 million Hong Kong dollars, with total assets of about 345.3 million Hong Kong dollars. The board of directors did not recommend the payment of interim dividends. The company's shareholder equity increased slightly to approximately 244.3 million Hong Kong dollars. The company faces challenges including the global economic situation, downward pressure on China's trade business, and the stable growth of China's cosmetic and health product market. The company will continue to promote the growth of its commodity trading business. The company's board of directors is diversified and has established nomination, remuneration, and audit committees to oversee corporate governance. The company complied with corporate governance regulations during the reporting period, but the chairman of the board did not attend the annual meeting. The stock ownership plan expired in 2023, with no stock options granted or exercised during the period.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more